One of the main strengths of this study is its hospital-based HER2+ patient cohort; it included all operable non-metastatic HER2+ breast cancer cases operated upon in Kuopio University hospital between 2001 and 2008 and thus it represents the real-world HER2+ breast cancer population very well. This evidence concerns the gene ERBB2 and breast cancer.